{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wu W"],"funding":["Sun Yat-Sen University Clinical Research 5010 Programme"],"pagination":["497"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5655944"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(1)"],"pubmed_abstract":["<h4>Background</h4>The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant endocrine therapy (NET) is an attractive alternative to NAC for ER-positive, HER2-negative cancer. However, a prior trial comparing NET with standard NAC in ER-positive tumor showed that the difference of response was not significant. Studies demonstrated that the mTOR inhibitor everolimus could sensitize breast tumors to endocrine therapy. A pilot open-label, randomized trial has been designed to evaluate the feasibility, efficacy and tolerability of neoadjuvant everolimus plus letrozol"],"journal":["Trials"],"pubmed_title":["Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial."],"pmcid":["PMC5655944"],"funding_grant_id":["2016015"],"pubmed_authors":["Liu J","Yang Y","Cao M","You N","Wu W","Deng H","Rao N"],"additional_accession":[]},"is_claimable":false,"name":"Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.","description":"<h4>Background</h4>The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant endocrine therapy (NET) is an attractive alternative to NAC for ER-positive, HER2-negative cancer. However, a prior trial comparing NET with standard NAC in ER-positive tumor showed that the difference of response was not significant. Studies demonstrated that the mTOR inhibitor everolimus could sensitize breast tumors to endocrine therapy. A pilot open-label, randomized trial has been designed to evaluate the feasibility, efficacy and tolerability of neoadjuvant everolimus plus letrozol","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Oct","modification":"2026-06-08T05:43:43.157Z","creation":"2019-03-27T02:59:52Z"},"accession":"S-EPMC5655944","cross_references":{"pubmed":["29070044"],"doi":["10.1186/s13063-017-2228-5"]}}